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Dear Editor,
We read with interest the article by Taheri et al. regard-
ing the efficacy of Hepatitis B vaccine in those who lost 
Hepatitis B surface antigen (HbsAg) during follow up (1). 
As the authors mentioned, a protective anti-HBs level de-
veloped in 24% of chronic HBsAg-positive subjects who 
had already lost their HBsAg after hepatitis B vaccination, 
and the remaining cases need to be monitored for occult 
HBV infection. Subjects with no response after hepatitis B 
vaccination may have low levels of HBsAg or have immu-
nologic tolerance to hepatitis B vaccination and no abil-
ity to produce anti-HBs antibody as reported previously 
(2). Detection of HBV DNA in the absence of a detectable 
HBsAg level and occasionally other HBV serologic mark-
ers is termed occult hepatitis B (OHB) (3). These patients 
can not only transmit HBV to others but also may prog-
ress to chronic hepatitis, cirrhosis, and hepatocellular 
carcinoma.  The  prevalence  and  outcomes  of  OHB  in 
chronic HBV-infected individuals have not yet been re-
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ported. On the other hand, patients who lost HBsAg and 
have not seroconverted to anti-HBs with no detectable 
HBV  DNA  are  frequently  seen  in  clinical  practice,  and 
the outcomes for this group of patients are not clear. A 
study by our research group on the long-term outcomes 
of chronic hepatitis B surface antigen (HBsAg) carriers in 
the general population in northeastern Greece showed 
that HBsAg to anti-HBs seroconversion was observed in 
10 out of 195 (5.1%) patients at the inactive carrier state, 
with an estimated annual prevalence rate of 1%. Addition-
ally, six patients lost HBsAg (3.1%) without developing an-
ti-HBs immunity. All patients who lost HBsAg during the 
follow up period were HBeAg negative and anti-HBe posi-
tive and had undetectable serum HBV-DNA and normal 
ALT levels (4). In another study, we determined that the 
frequency chronic HBV patients with isolated anti-HBc 
was 6% in the general population of northeastern Greece, 
where HBsAg endemicity is about 3% (5). Serum HBV-DNA 
levels were less than 2,000 IU/ml and were detected in 9 
out of 93 (9.7%) anti-HBc positive, anti-HBe positive indi-
viduals, of whom 3 developed anti-HBs during the follow 
up period despite the persistence of serum HBV-DNA (6). 
In patients with detectable levels of HBV-DNA, no mu-
tation was detected in the S gene. These subjects either 
have chronic HBV infection but lost HBsAg over time or 
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resolved HBV infection with a decrease in anti-HBs anti-
body levels below 10 IU/L (6). For patients with isolated 
anti-HBc antibody who receive the hepatitis B vaccina-
tion, several studies have reported significant anti-HBs 
levels of 91%–96% of the subjects (2, 7-9). Lok et al. reported 
no response rate after three doses of hepatitis B vaccine 
in 28% of 32 subjects with isolated anti-HBc antibody (2). 
Lai et al. reported no anti-HBs response in 22.9% of 48 cas-
es with isolated anti-HBc after three doses of the hepati-
tis B vaccination (9). Our data are in agreement with the 
results of the above studies and suggest a relatively low 
percentage (26%) of no anti-HBs response in patients who 
are anti-HBc positive only (unpublished data). Although 
Taheri et al. found that 24% of chronic HBsAg-positive sub-
jects who lost HBsAg developed anti-HBs after receiving 
the hepatitis B vaccination, we have to take into account 
spontaneous HBsAg seroconversion. Indeed, according 
to our results, 47.8% (163/341) of individuals with detect-
able anti-HBc levels at presentation developed anti-HBs 
immunity (annual rate of 9.5%) and had undetectable 
serum HBV-DNA during the observation period of up to 
17 years (10). Our data are in agreement with the results 
of Taheri et al. (1) that chronic HBsAg-positive cases who 
lost their HBsAg and are negative for HBV DNA mostly 
responded to hepatitis B vaccination. Additionally, these 
patients differed from the remaining patients who lost 
HBsAg during follow up and were positive for HBV DNA, 
who still might have OHB and must be followed up with.
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